• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

内分泌治疗与激素受体阳性、ERBB2 阴性、小体积乳腺癌女性总生存的关系。

Association of Endocrine Therapy With Overall Survival in Women With Small, Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.

机构信息

Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Department of Radiation Oncology, Massachusetts General Hospital, Boston.

出版信息

JAMA Netw Open. 2020 Aug 3;3(8):e2013973. doi: 10.1001/jamanetworkopen.2020.13973.

DOI:10.1001/jamanetworkopen.2020.13973
PMID:32833014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7445593/
Abstract

This cohort study examines the association of overall survival with endocrine therapy to treat hormone receptor–positive, -negative breast cancer.

摘要

本队列研究探讨了内分泌治疗治疗激素受体阳性、阴性乳腺癌与总生存的关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a77/7445593/dc59e6a8956f/jamanetwopen-3-e2013973-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a77/7445593/dc59e6a8956f/jamanetwopen-3-e2013973-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a77/7445593/dc59e6a8956f/jamanetwopen-3-e2013973-g001.jpg

相似文献

1
Association of Endocrine Therapy With Overall Survival in Women With Small, Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.内分泌治疗与激素受体阳性、ERBB2 阴性、小体积乳腺癌女性总生存的关系。
JAMA Netw Open. 2020 Aug 3;3(8):e2013973. doi: 10.1001/jamanetworkopen.2020.13973.
2
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.激素受体阳性乳腺癌女性的辅助内分泌治疗：美国临床肿瘤学会临床实践指南重点更新
J Oncol Pract. 2019 Feb;15(2):106-107. doi: 10.1200/JOP.18.00617. Epub 2018 Dec 5.
3
Association of Survival With Chemoendocrine Therapy in Women With Small, Hormone Receptor-Positive, ERBB2-Positive, Node-Negative Breast Cancer.激素受体阳性、表皮生长因子受体 2 阳性、淋巴结阴性的小体积乳腺癌患者接受化疗内分泌治疗的生存相关性。
JAMA Netw Open. 2020 Apr 1;3(4):e202507. doi: 10.1001/jamanetworkopen.2020.2507.
4
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.在绝经后 HR(+)、HER2(-)晚期乳腺癌中，双重阻断可改善无进展生存期，迎来新纪元。
Cancer Treat Rev. 2015 Feb;41(2):94-104. doi: 10.1016/j.ctrv.2014.12.011. Epub 2014 Dec 30.
5
Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy.内分泌治疗可改善激素反应型年轻乳腺癌患者的生存率。
Breast Cancer Res Treat. 2017 Sep;165(2):311-320. doi: 10.1007/s10549-017-4331-4. Epub 2017 Jun 10.
6
ERBB2 status and benefit from adjuvant tamoxifen in ERalpha-positive postmenopausal breast carcinoma.
Cancer Lett. 2001 Dec 28;174(2):173-8. doi: 10.1016/s0304-3835(01)00696-6.
7
Treatment of early-stage hormone receptor-positive breast cancer.早期激素受体阳性乳腺癌的治疗
Clin Adv Hematol Oncol. 2019 Nov;17(11):596-599.
8
Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself.在内分泌反应性乳腺癌中，比雌激素受体本身更好的预测因素。
Int J Gynecol Cancer. 2006;16 Suppl 2:533-7. doi: 10.1111/j.1525-1438.2006.00690.x.
9
Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.激素受体阳性乳腺癌中乳腺癌干细胞的免疫组织化学检测及其对内分泌治疗反应和临床结局的作用。
Oncology. 2012;82(3):168-74. doi: 10.1159/000336078. Epub 2012 Mar 15.
10
Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.雌激素受体阴性、孕激素受体阳性且人表皮生长因子受体2阴性乳腺癌的分子本质及内分泌反应性
BMC Med. 2015 Oct 5;13:254. doi: 10.1186/s12916-015-0496-z.

引用本文的文献

1
Adjuvant endocrine treatment strategies for non-metastatic breast cancer: a network meta-analysis.非转移性乳腺癌的辅助内分泌治疗策略：一项网状荟萃分析。
EClinicalMedicine. 2025 Feb 17;81:103116. doi: 10.1016/j.eclinm.2025.103116. eCollection 2025 Mar.
2
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers.全身治疗对MINDACT研究中患有小的、雌激素受体阳性、人表皮生长因子受体2阴性乳腺癌患者的益处。
NPJ Breast Cancer. 2024 Nov 2;10(1):97. doi: 10.1038/s41523-024-00670-2.
3
Sexual Health after a Breast Cancer Diagnosis: Addressing a Forgotten Aspect of Survivorship.

本文引用的文献

1
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.长期辅助内分泌治疗与女性乳腺癌幸存者心血管疾病风险：系统评价。
BMJ. 2018 Oct 8;363:k3845. doi: 10.1136/bmj.k3845.
2
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.基于 21 基因表达检测的乳腺癌辅助化疗。
N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.
3
Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.乳腺癌肿瘤大小、过度诊断与乳腺 X 线筛查效果
乳腺癌诊断后的性健康：关注幸存者被遗忘的一个方面。
J Clin Med. 2022 Nov 14;11(22):6723. doi: 10.3390/jcm11226723.
4
Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women.为老年女性的早期雌激素受体阳性乳腺癌进行个体化治疗。
Lancet Healthy Longev. 2022 Jan;3(1):e54-e66. doi: 10.1016/s2666-7568(21)00280-4. Epub 2022 Jan 5.
N Engl J Med. 2016 Oct 13;375(15):1438-1447. doi: 10.1056/NEJMoa1600249.
4
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.女性小细胞、淋巴结阴性乳腺癌的肿瘤亚型和治疗模式的结果：一项多机构研究。
J Clin Oncol. 2014 Jul 10;32(20):2142-50. doi: 10.1200/JCO.2013.53.1608. Epub 2014 Jun 2.
5
Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.直径一厘米及以下且腋窝淋巴结阴性的乳腺肿瘤患者的预后与治疗
J Natl Cancer Inst. 2001 Jan 17;93(2):112-20. doi: 10.1093/jnci/93.2.112.